Crystalloid cardioplegia route of delivery and cardiac troponin I release
- PMID: 8694609
Crystalloid cardioplegia route of delivery and cardiac troponin I release
Abstract
Background: Cardiac troponin I (CTn I) has been shown to be a marker of myocardial injury. Incomplete distribution of cardioplegic solution may be responsible for injury in jeopardized myocardial areas. The aim of this study was to compare CTn I release with respect to the route of delivery of crystalloid cardioplegia, either antegrade only or initially antegrade followed by retrograde cardioplegia for the remainder of the operation, in patients undergoing elective coronary artery bypass grafting.
Methods: Sixty patients were randomly assigned to one of two cardioplegia groups. Cardiac troponin I concentrations were measured in serial venous blood samples drawn just before cardiopulmonary bypass and after aortic unclamping at 6, 9, 12, and 24 hours and daily thereafter for 5 days. Analysis of variance with repeated measures was performed to test the effect of route of delivery, coronary disease, collateral circulation, risk of cardioplegia maldistribution, and number of grafts on release of CTn I.
Results: Compared with the antegrade route, the combined route offered no advantage in an unselected group of patients undergoing an elective first cardiac operation and having preserved left ventricular function. The CTn I concentration did not differ between groups for any of the samples considered. In patients with major left main coronary artery stenosis, CTn I release was significantly higher at hour 9 in the antegrade group than in the group with combined delivery.
Conclusions: A combined route of delivery of crystalloid cardioplegia is beneficial in patients with major stenosis of the left main coronary artery. Cardiac troponin I sensitivity is relevant in this study. Release of CTn I should be useful in determining the best form of myocardial protection for each patient.
Similar articles
-
Crystalloid versus cold blood cardioplegia and cardiac troponin I release.Circulation. 1997 Jul 1;96(1):316-20. Circulation. 1997. PMID: 9236451 Clinical Trial.
-
Release of cardiac troponin I in antegrade crystalloid versus cold blood cardioplegia.J Thorac Cardiovasc Surg. 1999 Sep;118(3):452-9. doi: 10.1016/s0022-5223(99)70182-0. J Thorac Cardiovasc Surg. 1999. PMID: 10469959 Clinical Trial.
-
Does retrograde administration of blood cardioplegia improve myocardial protection during first operation for coronary artery bypass grafting?Ann Thorac Surg. 1997 Nov;64(5):1256-61; discussion 1262. doi: 10.1016/S0003-4975(97)00900-4. Ann Thorac Surg. 1997. PMID: 9386688 Clinical Trial.
-
Myocardial protection for coronary bypass grafting: the Toronto Hospital perspective.Ann Thorac Surg. 1995 Sep;60(3):824-32. doi: 10.1016/0003-4975(95)00421-G. Ann Thorac Surg. 1995. PMID: 7677541 Review.
-
Is there any difference between blood and crystalloid cardioplegia for myocardial protection during cardiac surgery? A meta-analysis of 5576 patients from 36 randomized trials.Perfusion. 2012 Nov;27(6):535-46. doi: 10.1177/0267659112453754. Epub 2012 Jul 31. Perfusion. 2012. PMID: 22851314 Review.
Cited by
-
Prognostic value of troponin I levels for predicting adverse cardiovascular outcomes in postmenopausal women undergoing cardiac surgery.Anesth Analg. 2009 Mar;108(3):719-26. doi: 10.1213/ane.0b013e318193fe73. Anesth Analg. 2009. PMID: 19224775 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials